Home Overview Press Room Blog Publications For Students about us
Search

About Biopolitics, Parties, Pundits & Human Biotechnology


Policy decisions about human biotechnologies have typically been debated among elite commissions and experts. But controversy is increasingly spilling over into mainstream news media and political debates.

This trend has been most notable in the United States, with the emergence of human embryonic stem cell research as a political issue. Stem cell debates at the policy level have made this discussion far more visible to the public.

The Bush Administration's restrictions on federal funding for human embryonic stem cell research elevated the issue to the front pages of newspapers. Shortly after its announcement in 2001, partisan battle lines were drawn in ways that mirror the abortion rights divide.

Republicans hoped that opposition to research that destroys embryos would increase support among their party's religious conservative base. Democrats countered by assembling a coalition of patient advocates, biomedical researchers, and biotechnology entrepreneurs and appealed to moderate swing voters and Republicans who they believed would be swayed by promises of cures.

There were some notable exceptions to this partisan line-up. Some conservatives support embryonic stem cell research; some liberals and progressives who support the research in principle criticize aspects of its conduct and regulation. Unfortunately, the polarized debate has frequently distorted facts while obscuring a range of important social issues unrelated to the moral status of embryos.



Breaking Taboo, Swedish Scientist Seeks To Edit DNA Of Healthy Human Embryos[citing CGS' Marcy Darnovsky]by Rob SteinNPRSeptember 22nd, 2016CRISPR gene editing human embryos is a step toward attempts at producing genetically modified humans. It's not a technology to be taken lightly.
Why we need a law to prevent genetic discriminationby Yvonne Bombard, Ronald Cohn & Stephen SchererThe Globe and Mail [Canada]September 19th, 2016After unanimous passage through Canada's Senate, Bill S-201 on genetic data is now presented before the House of Commons.
Human Chimera Research’s Huge (and Thorny) Potentialby Paul KnoepflerWiredSeptember 19th, 2016Stem cell researcher notes a range of ethical questions on the table if the NIH moves forward with lifting its research ban.
US toughens rules for clinical-trial transparencyby Sara ReardonNature NewsSeptember 16th, 2016Under new HHS rule, researchers must register information on the design and results of trials within 21 days of enrolling their first patient-- regardless of outcome.
‘Motherless babies!’ How to create a tabloid science headline in five easy stepsby Gretchen VogelScience MagazineSeptember 14th, 2016A modest research report on cell division is translated as a hyperbolic breakthrough. Gretchen Vogel critiques the flaws of hype-driven, click-bait journalism.
Peru Fails to Deliver for Indigenous Womenby Shena CavalloopenDemocracySeptember 12th, 2016~300,000 poor, rural, and indigenous people forcibly sterilized according to state "quotas", but public prosecutor says no "crimes against humanity" charges for state actors.
When Evolution Fights Back Against Genetic Engineeringby Brooke BorelThe AtlanticSeptember 12th, 2016Gene drive raises irreversible threats to ecosystems and unpredictable consequences that cannot be vetted in controlled lab settings.
Seeking to Join Editas, Intellia, CRISPR Therapeutics Makes Long Awaited IPO Pushby Ben FidlerXconomySeptember 12th, 2016Emmanuelle Charpentier’s biotech firm files to go public (~$90M), joining other CRISPR-Cas9 co-discoverers: Jennifer Doudna (Intellia, $108M, 5/2016) and Feng Zhang (Editas, $98M, 2/2016).
DNA Dragnet: In Some Cities, Police Go From Stop-and-Frisk to Stop-and-Spitby Lauren KirchnerProPublicaSeptember 12th, 2016Private police databases expanding with DNA “voluntarily” collected from minors, without oversight or right to challenge.
Will Genetic Engineering Really Change Everything Forever? [Video Review]by Elliot HosmanSeptember 8th, 2016The hype surrounding CRISPR gene editing and a future of designer babies is on playback with a popular new video. Is its optimism justified? And who decides what’s inevitable?
Displaying 1-10 of 1413  
Next >> 
Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760